Korro Bio Q1 net loss narrows to $19.6M; cash at $157M; KRRO-121 filing on track for H2 2026

Korro Bio, Inc.

2026-Q1 EPS reported -$1.69

Net loss of $19.6M vs $23.4M in Q1 2025; R&D spend down to $12.9M from $19.7M.
Cash, equivalents and marketable securities $157.1M as of March 31 (up from $85.2M), extending runway into H2 2028.
Closed oversubscribed $85M private placement led by Venrock Healthcare Capital Partners.
KRRO-121 regulatory filing for UCD/HE on track for H2 2026; AATD GalNAc candidate expected Q2 2026.
No collaboration revenue due to 12-month pause of Novo Nordisk partnership.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Korro Bio, Inc. reported first quarter ended March 31, 2026 results: net income $19.6 million.

Period: first quarter ended March 31, 2026
Net income: $19.6 million
Result: reported results

Exact text from the filing

Korro’s net loss was $19.6 million for the three months ended March 31, 2026

View on SEC.gov

1 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.